Some Apple employees have become disillusioned with the group's culture, where some have thrived while others feel sidelined.Technologyread more
Biden has shown staying power at the top of a jammed Democratic field even as polling numbers for Sanders, Warren and Harris wax and wane.2020 Electionsread more
The FDIC on Tuesday votes to approve a five-agency revision of the post-crisis regulation known as the Volcker Rule.Financeread more
The yield curve is the only economic indicator pointing to a recession, according to Credit Suisse.Marketsread more
Amid fears of a recession, Domino's Pizza CEO Ritch Allison said Tuesday that the U.S. consumer is still strong.Restaurantsread more
Stocks slipped on Tuesday as investors digested a sharp rebound from a strong sell-off last week.US Marketsread more
Makan Delrahim, assistant attorney general for the antitrust division, said several state attorneys general have spoken to the Justice Department about starting their own...Technologyread more
With the official launch of the Apple Card, Goldman Sachs has embarked on a multi-decade journey to becoming a leader in consumer banking, CEO David Solomon says.Financeread more
These are the stocks posting the largest moves midday.Market Insiderread more
The move comes as Facebook continues to grapple with its privacy practices and lawmakers' scrutiny over how it uses personal data to display ads. But it probably won't have...Technologyread more
For investors still haunted by last week's monster sell-off, the market's comeback is set to last, according to J.P. Morgan's quant guru.Marketsread more
A week ago, activist investor Dan Loeb turned a brighter spotlight on Amgen when his firm, Third Point, highlighted its investment in the biotechnology company and made a bold suggestion: that the drugmaker split up.
"It is well‐established that disparate business units generally benefit from operating separately due to distinct corporate cultures, superior efficiencies, and a greater focus for employees and management alike," Third Point said in its Oct. 21 investor letter. "Given the diverse nature of its assets—cash‐generative Mature Products and R&D‐intensive Growth Products—we believe that Amgen could benefit from a separation into distinct operating units with separate financial statements and should seriously consider separating into two companies."
Amgen's answer? In short, it doesn't make sense.
Chief Executive Officer Bob Bradway cited the company's consolidated supply chain, noting it makes all of its 11 molecules through it, for his opinion.
"As we've looked at this, we've not seen a way through we think unlocks significant value for our shareholders," Bradway told analysts and investors Tuesday at Amgen's business review in New York. "What I'm not saying is, 'No, never,' but right now we're not convinced there's a way through that adds value for all of our shareholders."
Amgen's stock was trading up more than 4 percent mid-morning.
The company also said it's expanding a restructuring announced earlier this year, and cutting an additional 5 percent of its workforce to make a total reduction of 20 percent. Amgen also detailed plans to pay out about 60 percent of adjusted net income, on average, to shareholders through 2018, increase its dividend by 30 percent in the first quarter of 2015, and buy back about $2 billion in stock through next year.
The company estimated 2015 revenue of $20.8 billion to $21.3 billion, and adjusted earnings of $9.05 to $9.40 a share.
Read MoreAmgen beats Street, raises guidance